Two small companies developing therapeutic vaccines against hypertension are blazing a trail for immune treatments that address diseases of lifestyle with massive markets. But doubts linger over the safety of eliciting an immune response to normal body constituents. Jill U. Adams investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anonymous. Nat. Rev. Drug Discov. 7, 794 (2008).
Ostchega, Y. et al. J. Am. Geriatr. Soc. 55, 1056–1065 (2007).
Chobanian, A.V. et al. J. Am. Med. Assoc. 289, 2560–2572 (2003).
Munger, M.A., Van Tassell, B.W. & LaFleur, J. MedGenMed. 19, 58 (2007).
Michel, J.B. et al. Circulation 81, 1899–1910 (1990).
Cornuz, J. et al. PLoS ONE 3, e2547 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Adams, J. Hypertension's shot in the arm. Nat Biotechnol 26, 1327–1329 (2008). https://doi.org/10.1038/nbt1208-1327
Issue Date:
DOI: https://doi.org/10.1038/nbt1208-1327
